Havrix Junior (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Junior is indicated for active immunization against hepatitis A virus in children, typically administered as part of a routine pediatric vaccination schedule. The vaccine is used to reduce the risk of acute hepatitis A disease, to protect children traveling to endemic regions, and to support outbreak control measures in community settings.

• Primary series of two doses given at least six months apart for children aged 12 months to 15 years.
• Booster dose recommended for children at risk of continued exposure after the primary series.
• Administration before travel to areas with high hepatitis A prevalence, ideally at least two weeks prior to departure.
• Use in outbreak situations to rapidly increase herd immunity among susceptible children.
• Integration into national immunization programs as a safe option for pediatric hepatitis A prevention.

Like other vaccines, Havrix Junior may cause mild to moderate reactions at the injection site or systemic symptoms, most of which resolve without medical intervention.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever occurring within 24‑48 hours after vaccination.
• Headache or mild fatigue lasting a day or two.
• Irritability or reduced appetite in younger children.

Serious

• Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, hives, or swelling of the face.
• High fever (≥40 °C) persisting more than 24 hours.
• Neurological symptoms such as seizures or unexplained crying.
• Persistent joint pain or swelling lasting several days.

Healthcare providers should assess individual health status before administering Havrix Junior and follow recommended guidelines to minimize risks.

• Defer vaccination in children with known severe allergy to any vaccine component, including algeldrate.
• Postpone if the child has a moderate or severe acute illness with fever.
• Observe the patient for at least 15 minutes after injection for immediate hypersensitivity reactions.
• Use caution in children with compromised immune systems; vaccine efficacy may be reduced.
• Discuss vaccination timing with pregnant or breastfeeding mothers, as safety data are limited.
• Record any previous adverse reactions to hepatitis A vaccines in the medical history.

Havrix Junior does not have many documented drug interactions, but certain conditions and concurrent therapies may influence its administration or safety profile.

Avoid

• Concurrent administration of other live vaccines within four weeks, as it may affect immune response.
• Use in children receiving immunoglobulin therapy for hepatitis A prophylaxis within two weeks of vaccination.

Use with caution

• Concurrent use of immunosuppressive agents (e.g., corticosteroids) may diminish antibody response.
• Antipyretics such as acetaminophen or ibuprofen can be given to manage mild post‑vaccination symptoms, but should not be taken prophylactically before injection.
• Patients on anticoagulant therapy should be monitored for prolonged bleeding at the injection site.